JP2017528446A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528446A5
JP2017528446A5 JP2017508663A JP2017508663A JP2017528446A5 JP 2017528446 A5 JP2017528446 A5 JP 2017528446A5 JP 2017508663 A JP2017508663 A JP 2017508663A JP 2017508663 A JP2017508663 A JP 2017508663A JP 2017528446 A5 JP2017528446 A5 JP 2017528446A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
dlbcl
compound
diazepin
thieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017508663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528446A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/069092 external-priority patent/WO2016026912A1/en
Publication of JP2017528446A publication Critical patent/JP2017528446A/ja
Publication of JP2017528446A5 publication Critical patent/JP2017528446A5/ja
Pending legal-status Critical Current

Links

JP2017508663A 2014-08-19 2015-08-19 チエノトリアゾロジアゼピン化合物を用いるリンパ腫の治療方法 Pending JP2017528446A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462039072P 2014-08-19 2014-08-19
US62/039,072 2014-08-19
US201462086609P 2014-12-02 2014-12-02
US62/086,609 2014-12-02
PCT/EP2015/069092 WO2016026912A1 (en) 2014-08-19 2015-08-19 Methods of treating lymphoma using thienotriazolodiazepine compounds

Publications (2)

Publication Number Publication Date
JP2017528446A JP2017528446A (ja) 2017-09-28
JP2017528446A5 true JP2017528446A5 (enExample) 2018-09-27

Family

ID=53900822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017508663A Pending JP2017528446A (ja) 2014-08-19 2015-08-19 チエノトリアゾロジアゼピン化合物を用いるリンパ腫の治療方法

Country Status (6)

Country Link
US (1) US9968620B2 (enExample)
EP (1) EP3182976A1 (enExample)
JP (1) JP2017528446A (enExample)
KR (1) KR20170037670A (enExample)
CN (1) CN107073011A (enExample)
WO (1) WO2016026912A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
JP2024522588A (ja) 2021-06-08 2024-06-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗がん化合物
WO2025120552A1 (ko) * 2023-12-07 2025-06-12 제이더블유중외제약 주식회사 헤테로사이클 유도체 함유 고체분산체, 이의 제조 방법, 이를 포함하는 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2412776C (en) 2000-06-16 2011-03-15 Mitsubishi Pharma Corporation Compositions controlling release ph range and/or speed
CA2710740C (en) * 2007-12-28 2016-07-19 Shinji Miyoshi Thienotriazolodiazepine compound as antitumor agent
US20140018353A1 (en) * 2012-06-25 2014-01-16 Oncoethix Sa Method of treating b-cell malignant cancers and t-cell malignant cancers using thienotriazolodiazepine compounds
KR20150100613A (ko) * 2012-09-28 2015-09-02 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 함유하는 약제학적 제제
WO2015018520A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
US20160158246A1 (en) * 2013-08-06 2016-06-09 Oncoethix Gmbh Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
AU2015252940A1 (en) * 2014-05-02 2016-11-17 Kay NOEL Method of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+non-small cell lung cancer using thienotriazolodiazepine compounds

Similar Documents

Publication Publication Date Title
Wu et al. Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases
Azwar et al. Recent updates on mechanisms of resistance to 5-fluorouracil and reversal strategies in colon cancer treatment
Wang et al. Biological function of long non-coding RNA (LncRNA) Xist
Toh et al. Epigenetics of hepatocellular carcinoma
Mizuguchi et al. Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review
Kalla et al. MicroRNAs: new players in IBD
Zhang et al. Polo-like kinase 4’s critical role in cancer development and strategies for Plk4-targeted therapy
Modak et al. Probing p300/CBP associated factor (PCAF)-dependent pathways with a small molecule inhibitor
ES2604324T3 (es) Métodos y composiciones basadas en microARN para el diagnóstico y el tratamiento de cánceres sólidos
US20210254056A1 (en) Identification and targeted modulation of gene signaling networks
Hagood Beyond the genome: epigenetic mechanisms in lung remodeling
Guan et al. Induction of the cellular microRNA-29c by influenza virus contributes to virus-mediated apoptosis through repression of antiapoptotic factors BCL2L2
JP2017529332A5 (enExample)
JP2017514907A5 (enExample)
Valadkhan et al. lncRNAs in stress response
Witteveldt et al. MicroRNA-deficient mouse embryonic stem cells acquire a functional interferon response
Siddiqui et al. Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline—a review
JP2017528446A5 (enExample)
Huang et al. MicroRNAs serve as a bridge between oxidative stress and gastric cancer
Liu et al. MicroRNA as regulators of cancer stem cells and chemoresistance in colorectal cancer
Shen et al. Altered viral replication and cell responses by inserting microRNA recognition element into PB1 in pandemic influenza A virus (H1N1) 2009
JP2018048151A5 (enExample)
Schultz et al. Genome-wide miRNA response to anacardic acid in breast cancer cells
Yan et al. Epigenetics and ocular diseases: from basic biology to clinical study
Manna et al. Non-coding RNAs: regulating disease progression and therapy resistance in hepatocellular carcinoma